Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab + Bevacizumab in Advanced/Metastatic Gynecological Cancer Overexpressing FGFR2b
NCT07146919Phase 2Withdrawn
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bemarituzumab in endometrial carcinoma, ovarian cancer and Cervical Cancer (CC) (3 arms), sponsored by Centre Léon Bérard. Primary endpoints: Maximum Tolerated Dose at 6 weeks, Recommended Phase 2 Dose at 6 weeks and 1 more. Planned start Oct 2025; status: withdrawn.
02
Drugs
bemarituzumab
03
Conditions
endometrial carcinomaovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT07146919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146919.